Cetuximab (anti-EGFR)

Cetuximab (anti-EGFR: epidermal growth factor receptor), marketed under the brand name Erbitux, is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. The antibody-drug conjugate (ADC) Cetuximab saratolacan, also known as Akalux, is a novel treatment for unresectable locally advanced or recurrent head and neck cancer has been approved in Japan. This ADC drug is a conjugate of Cetuximab with a photosensitizer called IR700 through linker. This biosimilar antibody is used for research only. MW: 145.781 KD.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG1
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human EGFR, 0.39 nM(Kd)
Clone	Cetuximab biosimilar
Conjugate	Unconjugated
Purity	99%
Molecular Weight	145.781 KD
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0